We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cost-Effectiveness of Media for Melioidosis Diagnosis Reviewed

By LabMedica International staff writers
Posted on 09 Aug 2019
Melioidosis is a frequently fatal disease caused by a soil bacterium called Burkholderia pseudomallei that is widespread in the rural tropics. The yield of B. pseudomallei from sites with a normal flora is increased by culture using selective, differential media such as Ashdown’s agar and selective broth.

Because staff are often not familiar with B. pseudomallei and because it may be hidden if it is outgrown by other bacteria, special culture media can help laboratories diagnose the disease. However, this costs more money so it is not always done even in areas where the disease is known to be present.

A team of international scientists led by the University of Oxford (Oxford, England) reviewed the results of all cultures in the microbiology laboratories of a hospital in Laos and a Hospital for Children in Cambodia, in 2017. They identified patients with melioidosis who were only diagnosed as a result of culture of non-sterile sites and established the total number of such samples cultured using selective media and the associated costs in each laboratory.

The investigators then conducted a rudimentary cost-effectiveness analysis by determining the incremental cost-effectiveness ratio (ICER) per DALY averted and compared this against the 2017 GDP per capita in each country. In both laboratories, colonies suspected of being B. pseudomallei were screened by Gram stain, oxidase test and latex agglutination. Routine confirmation of identity was by API 20NE.

The team reported that overall, 29 patients in Laos and nine in Cambodia (20% and 16.9% of all culture-positive patients respectively) would not have been diagnosed without the use of selective media, the majority of whom (18 and eight respectively) were diagnosed by throat swab culture. The cost per additional patient detected by selective culture was approximately USD100 in Laos and USD39 in Cambodia. Despite the different patient populations (all ages in Laos versus only children in Cambodia) and testing strategies (all samples in Laos versus based on clinical suspicion in Cambodia), selective B. pseudomallei culture proved highly cost effective in both settings, with an ICER of ~USD170 and ~USD28 in Laos and Cambodia, respectively.

The authors concluded that in any patients with suspected melioidosis they recommend that, in addition to blood culture, a throat swab, or a good quality sputum sample if available, should be sent specifically for culture on Ashdown’s agar (ASH) and in Ashdown’s selective enrichment broth subcultured onto Ashdown’s agar only (SB), and a centrifuged deposit of urine should also be cultured on ASH. In areas of high melioidosis incidence, they also recommend the use of ASH and SB for any sputum and endotracheal aspirates received from patients with pneumonia. The study was published on July 15, 2019, in the journal PLOS Neglected Tropical Diseases.

Related Links:
University of Oxford


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Immunofluorescence Analyzer
MPQuanti
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.